EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France

Alexandre Dormoy, Magalie Haissaguerre, Géraldine Vitellius, Christine Do Cao, Aurore Geslot, Delphine Drui, Hélène Lasolle iD, Oceana Vieira-Pinto, Sylvie Salenave, Maud François, Marie Puerto, Hélène Du Boullay und 11 weitere

The Journal of Clinical Endocrinology & Metabolism · 17.05.2023 · 108 (6) · 1475-1487

DOI: 10.1210/clinem/dgac691 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 06.12.2022. Verfasst von Alexandre Dormoy und 22 weiteren Autor:innen. Beteiligte Einrichtung: Paris-Saclay University; Assistance Publique-Hôpitaux de Paris, Department of Endocrinology, Reference Centre for Rare Pituitary Diseases HYPO, Bicêt…. Hauptthemen laut MEDLINE: Cushing Syndrome, Adrenal Insufficiency. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Prospective studies have demonstrated the efficacy of osilodrostat in Cushing disease. No study has evaluated osilodrostat in a series of patients with paraneoplastic Cushing syndrome/ectopic adrenocorticotropin syndrome (PNCS/EAS).

Objective

This work aimed to evaluate in France the real-world efficacy and safety of osilodrostat in patients with PNCS/EAS.

Methods

A total of 33 patients with PNCS/EAS with intense/severe hypercortisolism were involved in this retrospective, multicenter, real-world study. Patients received osilodrostat between May 2019 and March 2022 at a median initial dose (range) of 4 mg/day (1-60) and maximum dose, 20 mg/day (4-100), first under patient then cohort temporary authorizations and after marketing authorization. Regimens used titration (n = 6), block and replace (n = 16), or titration followed by block and replace (n = 11).

Results

In 11 patients receiving osilodrostat as first-line monotherapy, median 24-hour urinary free cortisol (24h-UFC) decreased dramatically (from 26 × upper limit of normal [ULN; 2.9-659] to 0.11 × ULN [0.08-14.9]; P < .001). In 9 of them, 24h-UFC normalization was achieved in 2 weeks (median). Thirteen additional patients were previously treated with classic steroidogenesis inhibitors but 10 of these 13 were not controlled. In these patients, osilodrostat monotherapy, used as second line, induced a significantly decreased of 24h-UFC (from 2.6 × ULN [1.1-144] to 0.22 × ULN [0.12-0.66]; P < .01). Nine additional patients received osilodrostat in combination with another anticortisolic drug, decreasing 24h-UFC from 11.8 × ULN (0.3-247) to 0.43 × ULN (0.33-2.4) (P < .01). In parallel, major clinical symptoms/comorbidities improved dramatically with improvement in blood pressure, hyperglycemia, and hypokalemia, allowing the discontinuation or dose reduction of patient treatments. Adrenal insufficiency (grade 3-4) was reported in 8 of 33 patients.

Conclusion

Osilodrostat is a rapidly efficient therapy for PNCS/EAS with severe/intense hypercortisolism. Osilodrostat was generally well tolerated; adrenal insufficiency was the main side effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cushing SyndromeAdrenal InsufficiencyHumansProspective StudiesRetrospective StudiesAdrenocorticotropic HormoneHydrocortisoneImidazolesPyridines

Stichwörter der Autor:innen

Cushing syndromeadrenal insufficiencycorticotropinectopic adrenocorticotropic hormone syndromehypokalemianeuroendocrine tumorsosilodrostatparaneoplastic Cushing syndromesteroidogenesis inhibitors

Substanzen

Adrenocorticotropic HormoneHydrocortisoneOsilodrostatImidazolesPyridines

Autor:innen und Institutionen

  • Paris-Saclay University; Assistance Publique-Hôpitaux de Paris, Department of Endocrinology, Reference Centre for Rare Pituitary Diseases HYPO, Bicêtre Hospital, Le Kremlin-Bicêtre, F-94275, France.
  • Bordeaux University, Department of Endocrinology, Haut-Lévêque Hospital, F-33600, Pessac, France.
  • Department of Endocrinology, Robert Debré University Hospital, F-51100, Reims, France.
  • Department of Endocrinology, Centre Hospitalier Régional Universitaire de Lille, F-59037, Lille, France.
  • Department of Endocrinology and Metabolic Diseases, Larrey University Hospital, F-31059, Toulouse, France.
  • Department of Endocrinology, Institut du Thorax, CHU de Nantes, and Nantes Université, Hôpital Nord, F-44000 Nantes, France.

ORCID-Profile: Hélène Lasolle, Philippe Chanson, Frédéric Castinetti, Olivier Chabre, Eric Baudin, Gérald Raverot, Antoine Tabarin, Jacques Young

Zitieren

APA

Dormoy, A., Haissaguerre, M., Vitellius, G., Do Cao, C., Geslot, A., Drui, D., Lasolle, H., Vieira-Pinto, O., Salenave, S., François, M., Puerto, M., Boullay, H. D., Mayer, A., Rod, A., Laurent, C., Chanson, P., Reznik, Y., Castinetti, F., Chabre, O., …, & Young, J. (2023). Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France. The Journal of Clinical Endocrinology & Metabolism, 108(6), 1475-1487. https://doi.org/10.1210/clinem/dgac691

Vancouver

Dormoy A, Haissaguerre M, Vitellius G, Do Cao C, Geslot A, Drui D, et al. Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France. The Journal of Clinical Endocrinology & Metabolism. 2023;108(6):1475-1487. doi:10.1210/clinem/dgac691

BibTeX
@article{Dormoy2023,
  author = {Dormoy, Alexandre and Haissaguerre, Magalie and Vitellius, Géraldine and Do Cao, Christine and Geslot, Aurore and Drui, Delphine and Lasolle, Hélène and Vieira-Pinto, Oceana and Salenave, Sylvie and François, Maud and Puerto, Marie and Boullay, Hélène Du and Mayer, Anne and Rod, Anne and Laurent, Claire and Chanson, Philippe and Reznik, Yves and Castinetti, Frédéric and Chabre, Olivier and Baudin, Eric and Raverot, Gérald and Tabarin, Antoine and Young, Jacques},
  title = {Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  volume = {108},
  number = {6},
  pages = {1475--1487},
  doi = {10.1210/clinem/dgac691}
}
Kostenlos starten →